Floatz logo

Eliglustat

Cerebroside Lipidosis Syndrome

Genzyme, a Sanofi CompanySmall moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Cerebroside Lipidosis Syndrome cohort.

Asset / SponsorPhaseRating
Taliglucerase Alfa
Protalix
Phase 4A
Velaglucerase Alfa
Takeda
Phase 4A
Cerezyme
Sanofi
Phase 4A
Cerezyme
Sanofi
Phase 4BBB
Eliglustat
Peking Union Medical College Hospital
Phase 3BBB

View all 30 →

Same molecule, other indications

Eliglustat is also rated in:

Gaucher Disease, Type 1Dormant
BBB
Indicative ·
76 / 100
View asset →
Gaucher diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Gaucher Disease Type 1Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →